Alliance for Pandemic Preparedness

August 26, 2020

Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post Hoc Analysis of LOTUS China Trial

Category:

Topic:

Keywords (Tags):

  • Patients with severe COVID-19 (n=191) enrolled in the LOTUS China trial testing lopinavir for suppression of SARS-CoV-2 nearly all (>90%) developed IgM and IgG antibodies against nucleocapsid (N), spike protein (S), and the receptor-binding domain (RBD), and also produced neutralizing antibodies (NAbs), but these did not correlate clearly with clinical outcomes. The levels of IgG antibodies against N, S and RBD were related to viral clearance. The NAbs titers increased over time in both survivors and non-survivors and correlated with IgG antibodies against N, S and RBD, but NAbs titers were not associated with viral load or survival, indicating that NAbs might not be sufficient for the viral clearance of SARS-CoV-2 during disease progression.

Ren et al. (Aug 25, 2020). Antibody Responses and Clinical Outcomes in Adults Hospitalized with Severe COVID-19: A Post Hoc Analysis of LOTUS China Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaa1247